<h4>Background</h4>Folate receptor alpha (FRα, FOLR1) is the required biomarker for mirvetuximab soravtansine, a treatment option for patients with platinum-resistant ovarian cancer. The gene discussed is FOLR1; the disease is ovarian carcinoma.